Cardiac side effects of chemotherapy with anthracyclines in sarcoma patients assessed by cardiac MRI

Assessment of the predictive value of cardiac MRI in anthracycline-induced cardiomyopathy in sarcoma patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12210850

Enrollment

Registered

2017-08-11

Start date

2014-10-01

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anthracycline-induced cardiomyopathy in patients with sarcoma Injury, Occupational Diseases, Poisoning

Interventions

Cardiac tissue morphology is assessed in sarcoma patients treated with anthracycline-based chemotherapy using cardiac MRI. Patients receive at least three cardiac MRI scans: before start of chemothera

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed sarcoma diagnosis 2. Planned chemotherapy with anthracyclines (cumulative dose >300 mg/m2 doxorubicin-equivalent) 3. Age at least 18 years (no upper limit)

Exclusion criteria

Exclusion criteria: 1. Any contraindication for contrast-based MRI 2. Chronic renal failure (glomerular filtration rate <30ml/min) 3. Previous participation in this study

Design outcomes

Primary

Measure	Time frame
Myocardial T1 and T2 times, measured using parametric mapping techniques before start of chemotherapy (baseline), 24-48 hours after the first treatment and 3-4 weeks after completion of chemotherapy (usually after 4-5 months).	—

Secondary

Measure	Time frame
Measured before start of chemotherapy (baseline), 24-48 hours after the first treatment and 3-4 weeks after completion of chemotherapy (usually after 4-5 months): 1. Left and right atrial and ventricular size and function, measured in CINE sequences 2. Detection and size of myocardial fibrosis using late gadolinium enhancement techniques 3. Detection of arrhythmia using ECG 4. Laboratory blood analysis parameters (NTproBNP, hematocrit, high sensitive troponin T, glomerular filtration rate)	—

Measure

Time frame

Measured before start of chemotherapy (baseline), 24-48 hours after the first treatment and 3-4 weeks after completion of chemotherapy (usually after 4-5 months): 1. Left and right atrial and ventricular size and function, measured in CINE sequences 2. Detection and size of myocardial fibrosis using late gadolinium enhancement techniques 3. Detection of arrhythmia using ECG 4. Laboratory blood analysis parameters (NTproBNP, hematocrit, high sensitive troponin T, glomerular filtration rate)

—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 22, 2026